vs
Side-by-side financial comparison of HALOZYME THERAPEUTICS, INC. (HALO) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
SCANSOURCE, INC. is the larger business by last-quarter revenue ($766.5M vs $451.8M, roughly 1.7× HALOZYME THERAPEUTICS, INC.). SCANSOURCE, INC. runs the higher net margin — 2.2% vs -31.3%, a 33.5% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs 2.5%). HALOZYME THERAPEUTICS, INC. produced more free cash flow last quarter ($217.6M vs $28.9M). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs 0.9%).
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
HALO vs SCSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $451.8M | $766.5M |
| Net Profit | $-141.6M | $16.5M |
| Gross Margin | 82.6% | 13.4% |
| Operating Margin | -20.6% | 2.3% |
| Net Margin | -31.3% | 2.2% |
| Revenue YoY | 51.6% | 2.5% |
| Net Profit YoY | -203.3% | -3.3% |
| EPS (diluted) | $-1.13 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $451.8M | $766.5M | ||
| Q3 25 | $354.3M | $739.6M | ||
| Q2 25 | $325.7M | $812.9M | ||
| Q1 25 | $264.9M | $704.8M | ||
| Q4 24 | $298.0M | $747.5M | ||
| Q3 24 | $290.1M | $775.6M | ||
| Q2 24 | $231.4M | $746.1M | ||
| Q1 24 | $195.9M | $752.6M |
| Q4 25 | $-141.6M | $16.5M | ||
| Q3 25 | $175.2M | $19.9M | ||
| Q2 25 | $165.2M | $20.1M | ||
| Q1 25 | $118.1M | $17.4M | ||
| Q4 24 | $137.0M | $17.1M | ||
| Q3 24 | $137.0M | $17.0M | ||
| Q2 24 | $93.2M | $16.1M | ||
| Q1 24 | $76.8M | $12.8M |
| Q4 25 | 82.6% | 13.4% | ||
| Q3 25 | 84.4% | 14.5% | ||
| Q2 25 | 85.8% | 12.9% | ||
| Q1 25 | 81.7% | 14.2% | ||
| Q4 24 | 85.9% | 13.6% | ||
| Q3 24 | 83.0% | 13.1% | ||
| Q2 24 | 82.9% | 13.0% | ||
| Q1 24 | 85.5% | 12.6% |
| Q4 25 | -20.6% | 2.3% | ||
| Q3 25 | 61.5% | 3.5% | ||
| Q2 25 | 62.2% | 3.3% | ||
| Q1 25 | 53.4% | 3.2% | ||
| Q4 24 | 58.9% | 2.5% | ||
| Q3 24 | 56.3% | 2.3% | ||
| Q2 24 | 50.7% | 2.9% | ||
| Q1 24 | 48.8% | 2.3% |
| Q4 25 | -31.3% | 2.2% | ||
| Q3 25 | 49.5% | 2.7% | ||
| Q2 25 | 50.7% | 2.5% | ||
| Q1 25 | 44.6% | 2.5% | ||
| Q4 24 | 46.0% | 2.3% | ||
| Q3 24 | 47.2% | 2.2% | ||
| Q2 24 | 40.3% | 2.2% | ||
| Q1 24 | 39.2% | 1.7% |
| Q4 25 | $-1.13 | $0.75 | ||
| Q3 25 | $1.43 | $0.89 | ||
| Q2 25 | $1.33 | $0.87 | ||
| Q1 25 | $0.93 | $0.74 | ||
| Q4 24 | $1.06 | $0.70 | ||
| Q3 24 | $1.05 | $0.69 | ||
| Q2 24 | $0.72 | $0.66 | ||
| Q1 24 | $0.60 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.8M | $83.5M |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $48.8M | $910.9M |
| Total Assets | $2.5B | $1.7B |
| Debt / EquityLower = less leverage | 43.89× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $133.8M | $83.5M | ||
| Q3 25 | $419.7M | $124.9M | ||
| Q2 25 | $61.9M | $126.2M | ||
| Q1 25 | $176.3M | $146.3M | ||
| Q4 24 | $115.8M | $110.5M | ||
| Q3 24 | $154.3M | $145.0M | ||
| Q2 24 | $187.9M | $185.5M | ||
| Q1 24 | $164.6M | $159.1M |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $48.8M | $910.9M | ||
| Q3 25 | $503.9M | $914.0M | ||
| Q2 25 | $332.7M | $906.4M | ||
| Q1 25 | $482.3M | $901.7M | ||
| Q4 24 | $363.8M | $900.7M | ||
| Q3 24 | $452.7M | $920.9M | ||
| Q2 24 | $289.4M | $924.3M | ||
| Q1 24 | $177.8M | $944.1M |
| Q4 25 | $2.5B | $1.7B | ||
| Q3 25 | $2.2B | $1.7B | ||
| Q2 25 | $2.1B | $1.8B | ||
| Q1 25 | $2.2B | $1.7B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.1B | $1.8B | ||
| Q2 24 | $2.0B | $1.8B | ||
| Q1 24 | $1.8B | $1.8B |
| Q4 25 | 43.89× | — | ||
| Q3 25 | 3.00× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | — | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — | ||
| Q1 24 | 8.44× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $219.0M | $30.8M |
| Free Cash FlowOCF − Capex | $217.6M | $28.9M |
| FCF MarginFCF / Revenue | 48.2% | 3.8% |
| Capex IntensityCapex / Revenue | 0.3% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $644.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $219.0M | $30.8M | ||
| Q3 25 | $178.6M | $23.2M | ||
| Q2 25 | $99.7M | — | ||
| Q1 25 | $154.2M | $66.1M | ||
| Q4 24 | $178.5M | $-6.2M | ||
| Q3 24 | $115.4M | $44.8M | ||
| Q2 24 | $55.8M | — | ||
| Q1 24 | $129.4M | $160.2M |
| Q4 25 | $217.6M | $28.9M | ||
| Q3 25 | $175.6M | $20.8M | ||
| Q2 25 | $98.1M | — | ||
| Q1 25 | $153.3M | $64.6M | ||
| Q4 24 | $175.4M | $-8.2M | ||
| Q3 24 | $113.9M | $42.5M | ||
| Q2 24 | $53.2M | — | ||
| Q1 24 | $125.9M | $157.7M |
| Q4 25 | 48.2% | 3.8% | ||
| Q3 25 | 49.6% | 2.8% | ||
| Q2 25 | 30.1% | — | ||
| Q1 25 | 57.9% | 9.2% | ||
| Q4 24 | 58.9% | -1.1% | ||
| Q3 24 | 39.3% | 5.5% | ||
| Q2 24 | 23.0% | — | ||
| Q1 24 | 64.3% | 21.0% |
| Q4 25 | 0.3% | 0.3% | ||
| Q3 25 | 0.9% | 0.3% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 1.0% | 0.3% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 1.1% | 0.2% | ||
| Q1 24 | 1.8% | 0.3% |
| Q4 25 | — | 1.87× | ||
| Q3 25 | 1.02× | 1.17× | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 1.31× | 3.79× | ||
| Q4 24 | 1.30× | -0.36× | ||
| Q3 24 | 0.84× | 2.64× | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 1.68× | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
